Format

Send to

Choose Destination
Diabetes Obes Metab. 2017 Jun;19(6):906-908. doi: 10.1111/dom.12885. Epub 2017 Mar 17.

Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.

Author information

1
Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
2
Gastrounit, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.
3
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
4
The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Abstract

Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose upon doctors the obligation to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high-quality RCTs included a total of 9347 GLP-1RA-treated and 9353 placebo-treated patients with type 2 diabetes. Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI, 0.47-1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP-1RA increases the risk of AP in patients with type 2 diabetes.

KEYWORDS:

GLP-1 analogue; antidiabetic drug; incretin therapy; liraglutide; meta-analysis; type 2 diabetes

PMID:
28105738
DOI:
10.1111/dom.12885
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center